Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of ⁶⁴CuCl₂ in humans and to assess the ability of ⁶⁴CuCl₂ PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent ⁶⁴CuCl₂ PET/CT, ¹⁸F-choline PET/CT, and multiparametric MRI within 15 d of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available; clinical or laboratory response; and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions, and radiation dosimetry of ⁶⁴CuCl₂ were evaluated. Results: From a dosimetric point of view, an administered dose of 200 MBq for ⁶⁴CuCl₂ translated into a 5.7-mSv effective dose. Unlike ¹⁸F-choline, ⁶⁴CuCl₂ was not excreted or accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum ⁶⁴CuCl₂ uptake at the sites of PCa relapse was observed 1 h after tracer injection. In our cohort, ⁶⁴CuCl₂ PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of ¹⁸F-choline PET/CT and multiparametric MRI were 56% and 74%, respectively. The difference between the DRs of ⁶⁴CuCl₂ PET/CT and ¹⁸F-choline PET/CT was statistically significant (P < 0.001). Interestingly, on considering prostate-specific antigen (PSA) value, ⁶⁴CuCl₂ PET/CT had a higher DR than ¹⁸F-choline PET/CT in patients with a PSA of less than 1 ng/mL. Conclusion: The biodistribution of ⁶⁴CuCl₂ is more suitable than that of ¹⁸F-choline for exploring the pelvis and prostatic bed. The ⁶⁴CuCl₂ effective dose is like those of other established PET tracers. In patients with biochemical relapse and a low PSA level, ⁶⁴CuCl₂ PET/CT shows a significantly higher DR than ¹⁸F-choline PET/CT.

我们的目标是评估人体内⁶⁴ CuCl ₂的生物分布，动力学和辐射剂量，并评估⁶⁴ CuCl ₂ PET / CT在生化复发患者中检测前列腺癌（PCa）复发的能力。方法：我们前瞻性评估了50例PCa手术或外照射治疗后生化复发的患者。所有患者均接受⁶⁴ CuCl ₂ PET / CT，¹⁸彼此之间在15天内进行F-胆碱PET / CT和多参数MRI检查。经验丰富的读者对图像进行了解释，并计算了每种成像方式的检测率（DR）。组织病理学（如果有）；临床或实验室反应；并采用多学科随访来确定疾病部位。同时，评估了⁶⁴ CuCl _2的生物分布，病变动力学和辐射剂量。结果：从剂量学的角度来看，200 MBq的⁶⁴ CuCl ₂给药剂量转化为5.7-mSv有效剂量。与¹⁸ F-胆碱不同，⁶⁴ CuCl ₂不会在尿道中排泄或积聚，因此可以进行彻底的骨盆探查。示踪剂注射1 h后，在PCa复发部位最大吸收⁶⁴ CuCl ₂。在我们的队列中，在50例患者中的41例中，有^64例CuCl ₂ PET / CT被证实为阳性，总DR为82％。¹⁸ F-胆碱PET / CT和多参数MRI的DR分别为56％和74％。⁶⁴ CuCl ₂ PET / CT和¹⁸ F-胆碱PET / CT的DR之间的差异具有统计学意义（P <0.001）。有趣的是，考虑到前列腺特异性抗原（PSA）值，⁶⁴ CuCl ₂PSA小于1 ng / mL的患者，PET / CT的DR高于¹⁸ F-胆碱PET / CT。结论：⁶⁴ CuCl ₂的生物分布比¹⁸ F-胆碱的生物分布更适合探索骨盆和前列腺床。的⁶⁴的CuCl ₂的有效剂量是像那些其它已建立的PET示踪剂。在生化复发且PSA水平低的患者中，⁶⁴ CuCl ₂ PET / CT显示的DR显着高于¹⁸ F-胆碱PET / CT。